Oncogenic KRAS mutations result in a hyperactivated protein, and mutant KRAS is a key driver in many cancers, including pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC) and lung adenocarcinoma (LUAD)4. The gene discussed is KRAS; the disease is pancreatic ductal adenocarcinoma.